LPGO Stock Overview
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Lipigon Pharmaceuticals AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.37 |
| 52 Week High | kr0.82 |
| 52 Week Low | kr0.26 |
| Beta | 0.38 |
| 1 Month Change | -4.15% |
| 3 Month Change | -28.85% |
| 1 Year Change | -31.48% |
| 3 Year Change | -95.55% |
| 5 Year Change | n/a |
| Change since IPO | -96.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| LPGO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 24.8% | 0.2% | 1.8% |
| 1Y | -31.5% | -4.3% | 10.7% |
Return vs Industry: LPGO underperformed the Swedish Biotechs industry which returned -5.1% over the past year.
Return vs Market: LPGO underperformed the Swedish Market which returned 7.8% over the past year.
Price Volatility
| LPGO volatility | |
|---|---|
| LPGO Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: LPGO's share price has been volatile over the past 3 months.
Volatility Over Time: LPGO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | Stefan Nilsson | www.lipigon.se |
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia.
Lipigon Pharmaceuticals AB (publ) Fundamentals Summary
| LPGO fundamental statistics | |
|---|---|
| Market cap | kr46.78m |
| Earnings (TTM) | -kr12.13m |
| Revenue (TTM) | kr16.41m |
2.9x
P/S Ratio-3.9x
P/E RatioIs LPGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LPGO income statement (TTM) | |
|---|---|
| Revenue | kr16.41m |
| Cost of Revenue | kr21.52m |
| Gross Profit | -kr5.12m |
| Other Expenses | kr7.01m |
| Earnings | -kr12.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | -31.19% |
| Net Profit Margin | -73.92% |
| Debt/Equity Ratio | 0% |
How did LPGO perform over the long term?
See historical performance and comparison